MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

• ClinicalTrials.gov Identifier: NCT00048061
• Recruitment Status: Completed
• First Posted: October 25, 2002
• Results First Posted: May 30, 2016
• Last Update Posted: March 29, 2018
• Sponsor: Hoffmann-La Roche
• Information provided by (Responsible Party): Hoffmann-La Roche

Tracking Information

• First Submitted Date: October 24, 2002
• First Posted Date: October 25, 2002
• Results First Submitted Date: February 5, 2016
• Results First Posted Date: May 30, 2016
• Last Update Posted Date: March 29, 2018
• Study Start Date: April 2002
• Actual Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 22, 2016)

Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 - L4) Bone Mineral Density [ Time Frame: From Baseline (Month 0) to Month 12 ]

Relative change in Bone Mineral Density (BMD) is the percentage change from baseline of BMD of vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center after 12 months of treatment. It is calculated as the sum of bone mineral content divided by the sum of area of all lumbar vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process at Month 12. Participants available at particular time point for assessment were included in the analysis.

• Original Primary Outcome Measures: Not Provided

Current Secondary Outcome Measures (submitted: April 22, 2016)

• Relative Change From Baseline at Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD [ Time Frame: From Baseline (Month 0) to Month 24 ]
  Relative change in BMD is the percentage change from baseline of BMD of vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center after 24 months of treatment. It is calculated as the sum of bone mineral content divided by the sum of area of all lumbar vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process at Month 24.
• Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD [ Time Frame: From Baseline (Month 0) to Months 12 and 24 ]
  The absolute change (g/cm^2) from baseline in mean BMD of the lumbar spine (L2 - L4) at one and two years. A difference in the mean values between the active groups and the control was calculated.
• Relative Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD [ Time Frame: From Baseline (Month 0) to Months 12 and 24 ]
  Proximal femur BMD was measured by dual-energy X ray absorptiometry at baseline, after one and two years of treatment and was read by a central reading center.
• Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD. [ Time Frame: From Baseline (Month 0) to Months 12 and 24 ]
  Proximal femur BMD was measured by dual-energy X-ray absorptiometry at baseline, after one and two years of treatment and was read by a central reading center
• Percentage of Participants With Mean Lumbar Spine (L2 - L4) BMD Above or Equal to Baseline at Months 12 and 24 [ Time Frame: Months 12 and 24 ]
  A participant is a responder if the mean lumber spine (L2 - L4) BMD had remained the same or increased above baseline.
• Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Months 12 and 24 [ Time Frame: Months 12 and 24 ]
  A participant is a responder if the mean total hip BMD had remained the same or increased above baseline.
• Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Months 12 and 24 [ Time Frame: Months 12 and 24 ]
  A participant is a responder if the mean trochanter BMD had remained the same or increased above baseline.
• Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Months 12 and 24 [ Time Frame: Months 12 and 24 ]
  A participant is a responder if the mean femoral neck BMD had remained the same or increased above baseline.
• Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24 [ Time Frame: Months 12 and 24 ]
  A participant is a responder if the mean total hip and mean lumbar spine BMD had remained the same or increased above baseline.
• Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24 [ Time Frame: Months 12 and 24 ]
  A participant is a responder if the mean trochanter and lumbar spine BMD had remained the same or increased above baseline.
• Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24 [ Time Frame: Months 12 and 24 ]
  A participant is a responder if the mean femoral neck and lumbar spine BMD had remained the same or increased above baseline.
• Relative Change In Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen [ CTX] ] to Months 3, 6, 12, and 24 [ Time Frame: From Baseline (Month 0) to Months 3, 6, 12, 24 ]
  Serum CTX, a biochemical marker of bone resorption, was assessed using the Elecsys S-CTX-I assay (an ElectroChemiLuminescence Immunoassay (ECLIA) Technique).
• Absolute Change In Baseline in Serum CTX to Months 12 and 24 [ Time Frame: From Baseline (Month 0) to Months 12 and 24 ]
  Serum CTX, a biochemical marker of bone resorption, was assessed using the Elecsys S-CTX-I assay (an ElectroChemiLuminescence Immunoassay (ECLIA) Technique).
• Number of Participants With Any Adverse Events and Serious Adverse Event [ Time Frame: Up to Month 24 ]
  An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
• Number Of Participants With Marked Laboratory Abnormalities [ Time Frame: Up to Month 24 ]
  Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from baseline. The reference range for hemoglobin was 110-200 (gram per liter [g/L]), hematocrit was 0.31-0.56 fraction, white blood cells (WBC) was 3.0-18.0 (10*9/L), serum glutamic-pyruvic transaminase (SGPT/ALT) was 0-110 IU/L, blood urea nitrogen (BUN) was 0.0-14.3 (millimoles per Liter [mmol/L]), Chloride was 95-115 (mmol/L), Potassium was 3.0 - 6.0 (mmol/L), Sodium was 130-150 (mmol/L), Calcium was 2.00-2.90 (mmol/L), Phosphate was 0.75 - 1.60 (mmol/L) and Creatinine was 0- 154 (micromoles/liter [umol/L].

• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
• Official Title: Randomized, Double-blind, Double Dummy, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of Monthly Oral Administration of 100 mg and 150 mg Ibandronate With 2.5 mg Daily Oral Ibandronate in Postmenopausal Osteoporosis
• Brief Summary: This study will compare the efficacy and safety of different treatment regimens of oral Bonviva tablets in women with post-menopausal osteoporosis. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double; Primary Purpose: Treatment
• Condition: Post Menopausal Osteoporosis

Intervention

• Drug: Ibandronate [Bonviva/Boniva]
  2.5mg po daily
• Drug: Ibandronate [Bonviva/Boniva]
  100mg po monthly on a single day
• Drug: Ibandronate [Bonviva/Boniva]
  100mg po monthly over 2 consecutive days
• Drug: Ibandronate [Bonviva/Boniva]
  150mg po monthly
• Dietary Supplement: Calcium
  500 mg/day
• Dietary Supplement: Vitamin D
  400 IU/day

Study Arms

• Active Comparator: Ibandronate 2.5 mg
  Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .
  Interventions:

  • Drug: Ibandronate [Bonviva/Boniva]
  • Dietary Supplement: Calcium
  • Dietary Supplement: Vitamin D
• Experimental: Ibandronate 50/50 mg
  Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.
  Interventions:

  • Drug: Ibandronate [Bonviva/Boniva]
  • Dietary Supplement: Calcium
  • Dietary Supplement: Vitamin D
• Experimental: Ibandronate 100 mg
  Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
  Interventions:

  • Drug: Ibandronate [Bonviva/Boniva]
  • Dietary Supplement: Calcium
  • Dietary Supplement: Vitamin D
• Experimental: Ibandronate 150 mg
  Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
  Interventions:

  • Drug: Ibandronate [Bonviva/Boniva]
  • Dietary Supplement: Calcium
  • Dietary Supplement: Vitamin D

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: January 18, 2008): 1609
• Original Enrollment: Not Provided
• Actual Study Completion Date: December 2004
• Actual Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• women 55-80 years of age;
• post-menopausal for >= 5 years;
• ambulatory.

Exclusion Criteria:

• malignant disease diagnosed within the previous 10 years (except basal cell cancer that has been successfully removed);
• breast cancer within the previous 20 years;
• allergy to bisphosphonates;
• previous treatment with an intravenous bisphosphonate at any time;
• previous treatment with an oral bisphosphonate within the last 6 months, >1 month of treatment within the last year, or >3 months of treatment within the last 2 years.

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 55 Years to 80 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Mexico, Norway, Poland, Romania, South Africa, Spain, Switzerland, United Kingdom, United States
• Removed Location Countries: Czech Republic

Administrative Information

• NCT Number: NCT00048061
• Other Study ID Numbers: BM16549
• Has Data Monitoring Committee: Not Provided
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Hoffmann-La Roche
• Study Sponsor: Hoffmann-La Roche
• Collaborators: Not Provided

Investigators

• Study Director: Clinical Trials; Hoffmann-La Roche

• PRS Account: Hoffmann-La Roche
• Verification Date: February 2018